Gilead Sciences Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy GILD?
Source: seekingalpha
- Performance Growth: Gilead's total product sales for 2025 reached $28.9 billion, up 1% year-over-year, exceeding the guidance range of $28.4 to $28.7 billion, primarily driven by strong growth in the HIV business, showcasing the company's competitive position in the market.
- HIV Business Performance: Fourth-quarter HIV sales were $5.8 billion, a 6% increase year-over-year, with full-year HIV sales reaching $20.8 billion, and projected growth of approximately 6% in 2026, reflecting the company's sustained leadership in the antiviral sector.
- New Product Outlook: Management anticipates up to 10 new product launches by 2027, with Yeztugo's revenue expected to surge from $150 million in 2025 to $800 million in 2026, indicating strong market potential in HIV prevention.
- Future Guidance: Gilead expects total product sales in 2026 to range between $29.6 billion and $30 billion, with non-GAAP diluted EPS projected between $8.45 and $8.85, indicating the company's financial health and growth potential moving forward.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GILD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 151.680
Low
105.00
Averages
137.88
High
154.00
Current: 151.680
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Gilead Sciences Q4 2025 Earnings Call Highlights
- Performance Growth: Gilead's total product sales for 2025 reached $28.9 billion, up 1% year-over-year, exceeding the guidance range of $28.4 to $28.7 billion, primarily driven by strong growth in the HIV business, showcasing the company's competitive position in the market.
- HIV Business Performance: Fourth-quarter HIV sales were $5.8 billion, a 6% increase year-over-year, with full-year HIV sales reaching $20.8 billion, and projected growth of approximately 6% in 2026, reflecting the company's sustained leadership in the antiviral sector.
- New Product Outlook: Management anticipates up to 10 new product launches by 2027, with Yeztugo's revenue expected to surge from $150 million in 2025 to $800 million in 2026, indicating strong market potential in HIV prevention.
- Future Guidance: Gilead expects total product sales in 2026 to range between $29.6 billion and $30 billion, with non-GAAP diluted EPS projected between $8.45 and $8.85, indicating the company's financial health and growth potential moving forward.
See More
Gilead Sciences Q4 2025 Results Beat Expectations but Guidance Falls Short
- Earnings Beat: Gilead's Q4 2025 non-GAAP EPS of $1.86 exceeded expectations by $0.03, demonstrating resilience in product sales despite pressures from higher R&D expenses.
- Sales Growth: Overall product sales increased by 5% year-over-year to approximately $7.9 billion, with HIV drug sales rising 6% to about $5.8 billion, indicating strong performance in core business areas.
- 2026 EPS Guidance: Gilead's forecast for 2026 non-GAAP EPS ranges from $8.45 to $8.85, with a midpoint of $8.65, falling short of the consensus estimate of $8.75, which contributed to a ~4% decline in after-hours trading.
- Cash Flow Position: As of 2025, Gilead reported cash, cash equivalents, and marketable debt securities totaling $10.6 billion, up from $10 billion at the end of 2024, reflecting the company's financial stability.
See More
Gilead Reports Fourth Quarter Earnings Growth
- Earnings Growth: Gilead Sciences reported a fourth-quarter net income of $2.183 billion, translating to an earnings per share (EPS) of $1.74, which marks a significant increase from last year's $1.783 billion and $1.42 EPS, indicating enhanced profitability.
- Adjusted Earnings: Excluding certain items, Gilead's adjusted earnings reached $2.329 billion, or $1.86 per share, showcasing robust performance in its core business and further solidifying market confidence.
- Revenue Increase: The company's revenue rose by 4.7% year-over-year to $7.925 billion, up from $7.569 billion last year, reflecting sustained demand for its products and an expansion of market share.
- Positive Market Outlook: With both revenue and earnings growth, Gilead Sciences strengthens its competitive position in the biopharmaceutical sector, which is expected to drive further investments and R&D activities to meet evolving market demands.
See More
Analysis of After-Hours Trading Performance of Multiple Companies
- Robinhood Revenue Decline: Robinhood's Q4 revenue of $1.28 billion fell short of the $1.34 billion expected by analysts, with transaction revenue also missing at $776 million, leading to a 7% drop in stock price, reflecting market concerns over its profitability.
- Lyft's Poor Performance: Lyft's stock dropped 15%, as its Q4 bookings of $5.07 billion met expectations, but its first-quarter adjusted EBITDA guidance of $120 million to $140 million fell short of the $139.8 million consensus, indicating pressure on profitability.
- Mattel's Disappointing Guidance: Mattel's stock plummeted 25%, with full-year adjusted earnings guidance ranging from $1.18 to $1.30 per share, significantly below the $1.77 expected by the market, and Q4 results also missed expectations, highlighting weakness in the toy market.
- Cloudflare's Strong Outlook: Cloudflare's stock surged 10% after projecting Q1 revenue between $620 million and $621 million, exceeding the $614 million consensus, and its Q4 results also surpassed analyst expectations, showcasing strong growth potential in the cloud networking market.
See More
Gilead's Weak Fiscal 2026 Guidance Pressures Stock
- Strong Earnings Report: Gilead's fourth-quarter earnings per share of $1.86 exceeded the market expectation of $1.81, indicating robust profitability despite the weak guidance for the upcoming fiscal year.
- Revenue Growth: The company reported quarterly revenue of $7.93 billion, surpassing the analyst estimate of $7.69 billion, reflecting the successful launch of Yeztugo and continued growth of Biktarvy and Descovy.
- Future Outlook: Gilead expects adjusted EPS for fiscal 2026 to range from $8.45 to $8.85, below the analyst estimate of $8.74, with revenue projected between $29.6 billion and $30 billion, slightly lower than the market expectation of $30.22 billion.
- Stock Price Reaction: In after-hours trading on Tuesday, Gilead's stock fell by 2.87% to $143, reflecting market concerns regarding the company's future guidance, which may impact investor confidence.
See More
GILEAD: FY26 PROJECTION INDICATES 10% YEAR-OVER-YEAR DECLINE IN CELL THERAPY DUE TO PERSISTENT COMPETITIVE CHALLENGES - PRESENTATION
Market Outlook: The FY26 outlook for cell therapy is projected to decline by 10% year-over-year.
Competitive Challenges: This decline is attributed to ongoing competitive headwinds in the industry.
See More
Gilead Sciences Q4 2025 Earnings Call Highlights
- Performance Growth: Gilead's total product sales for 2025 reached $28.9 billion, up 1% year-over-year, exceeding the guidance range of $28.4 to $28.7 billion, primarily driven by strong growth in the HIV business, showcasing the company's competitive position in the market.
- HIV Business Performance: Fourth-quarter HIV sales were $5.8 billion, a 6% increase year-over-year, with full-year HIV sales reaching $20.8 billion, and projected growth of approximately 6% in 2026, reflecting the company's sustained leadership in the antiviral sector.
- New Product Outlook: Management anticipates up to 10 new product launches by 2027, with Yeztugo's revenue expected to surge from $150 million in 2025 to $800 million in 2026, indicating strong market potential in HIV prevention.
- Future Guidance: Gilead expects total product sales in 2026 to range between $29.6 billion and $30 billion, with non-GAAP diluted EPS projected between $8.45 and $8.85, indicating the company's financial health and growth potential moving forward.
See More
Gilead Sciences Q4 2025 Results Beat Expectations but Guidance Falls Short
- Earnings Beat: Gilead's Q4 2025 non-GAAP EPS of $1.86 exceeded expectations by $0.03, demonstrating resilience in product sales despite pressures from higher R&D expenses.
- Sales Growth: Overall product sales increased by 5% year-over-year to approximately $7.9 billion, with HIV drug sales rising 6% to about $5.8 billion, indicating strong performance in core business areas.
- 2026 EPS Guidance: Gilead's forecast for 2026 non-GAAP EPS ranges from $8.45 to $8.85, with a midpoint of $8.65, falling short of the consensus estimate of $8.75, which contributed to a ~4% decline in after-hours trading.
- Cash Flow Position: As of 2025, Gilead reported cash, cash equivalents, and marketable debt securities totaling $10.6 billion, up from $10 billion at the end of 2024, reflecting the company's financial stability.
See More
Gilead Reports Fourth Quarter Earnings Growth
- Earnings Growth: Gilead Sciences reported a fourth-quarter net income of $2.183 billion, translating to an earnings per share (EPS) of $1.74, which marks a significant increase from last year's $1.783 billion and $1.42 EPS, indicating enhanced profitability.
- Adjusted Earnings: Excluding certain items, Gilead's adjusted earnings reached $2.329 billion, or $1.86 per share, showcasing robust performance in its core business and further solidifying market confidence.
- Revenue Increase: The company's revenue rose by 4.7% year-over-year to $7.925 billion, up from $7.569 billion last year, reflecting sustained demand for its products and an expansion of market share.
- Positive Market Outlook: With both revenue and earnings growth, Gilead Sciences strengthens its competitive position in the biopharmaceutical sector, which is expected to drive further investments and R&D activities to meet evolving market demands.
See More
Analysis of After-Hours Trading Performance of Multiple Companies
- Robinhood Revenue Decline: Robinhood's Q4 revenue of $1.28 billion fell short of the $1.34 billion expected by analysts, with transaction revenue also missing at $776 million, leading to a 7% drop in stock price, reflecting market concerns over its profitability.
- Lyft's Poor Performance: Lyft's stock dropped 15%, as its Q4 bookings of $5.07 billion met expectations, but its first-quarter adjusted EBITDA guidance of $120 million to $140 million fell short of the $139.8 million consensus, indicating pressure on profitability.
- Mattel's Disappointing Guidance: Mattel's stock plummeted 25%, with full-year adjusted earnings guidance ranging from $1.18 to $1.30 per share, significantly below the $1.77 expected by the market, and Q4 results also missed expectations, highlighting weakness in the toy market.
- Cloudflare's Strong Outlook: Cloudflare's stock surged 10% after projecting Q1 revenue between $620 million and $621 million, exceeding the $614 million consensus, and its Q4 results also surpassed analyst expectations, showcasing strong growth potential in the cloud networking market.
See More
Gilead's Weak Fiscal 2026 Guidance Pressures Stock
- Strong Earnings Report: Gilead's fourth-quarter earnings per share of $1.86 exceeded the market expectation of $1.81, indicating robust profitability despite the weak guidance for the upcoming fiscal year.
- Revenue Growth: The company reported quarterly revenue of $7.93 billion, surpassing the analyst estimate of $7.69 billion, reflecting the successful launch of Yeztugo and continued growth of Biktarvy and Descovy.
- Future Outlook: Gilead expects adjusted EPS for fiscal 2026 to range from $8.45 to $8.85, below the analyst estimate of $8.74, with revenue projected between $29.6 billion and $30 billion, slightly lower than the market expectation of $30.22 billion.
- Stock Price Reaction: In after-hours trading on Tuesday, Gilead's stock fell by 2.87% to $143, reflecting market concerns regarding the company's future guidance, which may impact investor confidence.
See More
GILEAD: FY26 PROJECTION INDICATES 10% YEAR-OVER-YEAR DECLINE IN CELL THERAPY DUE TO PERSISTENT COMPETITIVE CHALLENGES - PRESENTATION
Market Outlook: The FY26 outlook for cell therapy is projected to decline by 10% year-over-year.
Competitive Challenges: This decline is attributed to ongoing competitive headwinds in the industry.
See More
